Uperio 50mg 28 tablets — Made in Italy — Free Delivery

Product description

Uperio tablets are used to treat chronic heart failure in adult patients with reduced left ventricular ejection fraction.

Compound

One tablet contains (active ingredients) 24.3 mg of sacubitril and 25.7 mg of valsartan (in the form of a complex of the sodium salt of sacubitril and valsartan).

Excipients: microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crospovidone, magnesium stearate, talc, colloidal silicon dioxide, hypromellose, titanium dioxide (E 171), macrogol 4000, iron oxide, red (E 172), iron oxide, black (E 172).

Contraindications

• hypersensitivity to the active substance or to any of the excipients;
• simultaneous use with ACE inhibitors; "Uperio" can be taken if at least 36 hours have passed since the withdrawal of the ACE inhibitor;
• a history of angioedema with the use of ACE inhibitors or ARBs;
• hereditary or idiopathic angioedema;
• simultaneous use with medicinal products containing aliskiren in patients with diabetes mellitus or in patients with impaired renal function (rSKF <60 ml / minute / 1.73 m2);
• severe liver dysfunction, biliary cirrhosis and cholestasis;
• second and third trimester of pregnancy.

Mode of application

The medicinal product is intended for oral administration. The time of taking the preparation "Uperio" does not depend on the time of the meal. Swallow the tablets whole and drink with a glass of water.

The recommended initial dose of "Uperio" is one 100 mg tablet 2 times a day, except for the situations described below. The dose should be doubled after 2-4 weeks of admission so that the dose is one 200 mg tablet twice a day, provided that the patient is well tolerated.

If patients develop intolerance (systolic blood pressure (SBP) ≤ 95 mm Hg, symptomatic hypotension, hyperkalemia, impaired renal function), it is recommended to adjust the combination therapy, temporarily reduce the dose or discontinue therapy with Uperio.

There is limited information on the treatment of patients who are not taking ACE inhibitors or ARBs, or taking them in low doses. Therefore, for this category of patients, the recommended dose is 50 mg 2 times a day with a slow increase in the dose (doubling the daily dose once every 3-4 weeks).

It is not recommended to start treatment in patients with serum potassium> 5.4 mmol / L or CAT <100 mm Hg. An initial dose of 50 mg twice daily is recommended for patients with SBP ≥ 100–110 mm Hg. Uperio should not be used with an ACE inhibitor or ARB. Given the potential risk of developing angioedema with simultaneous use with an ACE inhibitor, the preparation should not be used if at least 36 hours have not passed since the withdrawal of the ACE inhibitor.

Valsartan in the form of a complex salt contained in the "Uperio" preparation has a higher bioavailability compared to valsartan, which is contained in other tablet preparations.

If the patient misses the preparation intake, he should take the next dose at the appointed time.

Application features

Pregnant

It is not recommended to take "Uperio" during the first trimester of pregnancy, and during the second and third trimesters of pregnancy, the preparation is contraindicated for use.

Given the potential risk of adverse reactions in children who are breastfeeding, it is not recommended to use the preparation during breastfeeding.

There are no data on the effect of "Uperio" on the human body. During studies of the preparation on male and female rats, reproductive disorders were revealed.

Children

The safety and effectiveness of the use of "Uperio" in children (under the age of 18) have not been established. No data available.

Drivers

Due to the possible occurrence of dizziness or increased fatigue, care should be taken when driving or operating other mechanisms.

Overdose

There are not enough data on overdose of the preparation "Uperio" in humans.

A single use of the preparation  at a dose of 1200 mg and multiple use at a dose of 900 mg was well tolerated by healthy volunteers.

The most likely symptom of an overdose is a pronounced decrease in blood pressure due to the antihypertensive effect of the active ingredients. In this case, symptomatic treatment is recommended. The likelihood of withdrawal of the preparation during hemodialysis is extremely low, given the high binding to blood plasma proteins.

Side effects

During therapy with the preparation "Uperio", the most frequently reported adverse reactions were hypotension, hyperkalemia and impaired renal function. There have been reports that patients taking Uperio developed angioedema.

Storage conditions

Store in its original packaging to protect from moisture at a temperature not exceeding 30 ° C, out of the reach of children.

Expiration date - 36 months.